Halozyme Therapeutics, Inc.HALONASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+45.1%
5Y CAGR+44.5%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+45.1%/yr
Annual compound
5Y CAGR
+44.5%/yr
Consistent
Percentile
P100
Near historical high
vs 5Y Ago
6.3x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$964.34M+46.9%
2024$656.54M+45.3%
2023$451.95M+43.2%
2022$315.51M+21.8%
2021$259.04M+69.3%
2020$152.96M+370.5%
2019$-56.56M+18.4%
2018$-69.33M-183.4%
2017$83.16M+204.6%
2016$-79.47M-